{"id":627,"date":"2020-11-05T06:06:14","date_gmt":"2020-11-05T06:06:14","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=627"},"modified":"2020-11-05T06:06:14","modified_gmt":"2020-11-05T06:06:14","slug":"03-nov-2020-hydroxychloroquine-did-not-prevent-severe-outcomes-or-improved-clinical-scores","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/03-nov-2020-hydroxychloroquine-did-not-prevent-severe-outcomes-or-improved-clinical-scores\/","title":{"rendered":"(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients<\/p>\n<p>https:\/\/doi.org\/10.1093\/ofid\/ofaa446<\/p>\n<p class=\"\">In a multicenter, double-blind randomized clinical trial (NCT04369742)of HCQ among patients hospitalized with laboratory-confirmed COVID-19, Subjects were randomized in a 1:1 ratio to HCQ or placebo for 5 days and followed for 30 days. The primary efficacy outcome was a severe disease progression composite end point (death, intensive care unit admission, mechanical ventilation, extracorporeal membrane oxygenation, and\/or vasopressor use) at day 14. Results: A total of 128 patients were included in the intention-to-treat analysis. Baseline demographic, clinical, and laboratory characteristics were similar between the HCQ (n = 67) and placebo (n = 61) arms. At day 14, 11 (16.4%) subjects assigned to HCQ and 6 (9.8%) subjects assigned to placebo met the severe disease progression end point, but this did not achieve statistical significance (P = .350). There were no significant differences in COVID-19 clinical scores, number of oxygen-free days, SARS-CoV-2 clearance, or adverse events between HCQ and placebo. HCQ was associated with a slight increase in mean corrected QT interval, an increased D-dimer, and a trend toward an increased length of stay. In hospitalized patients with COVID-19, our data suggest that HCQ does not prevent severe outcomes or improve clinical scores.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients https:\/\/doi.org\/10.1093\/ofid\/ofaa446 In a multicenter, double-blind randomized clinical trial (NCT04369742)of HCQ among patients hospitalized with laboratory-confirmed COVID-19, Subjects were randomized in a 1:1 ratio to HCQ or&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/03-nov-2020-hydroxychloroquine-did-not-prevent-severe-outcomes-or-improved-clinical-scores\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/627"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=627"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/627\/revisions"}],"predecessor-version":[{"id":628,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/627\/revisions\/628"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}